Financial Performance Highlights
- Standalone Revenue from Operations: ₹5.39 lakhs (FY26) vs Nil (FY25)
- Other Income: ₹2.17 lakhs (FY26) vs ₹52.59 lakhs (FY25)
- Total Expenses: ₹50.58 lakhs (FY26) vs ₹70.64 lakhs (FY25)
- Profit/Loss Before Tax: (₹43.02) lakhs (FY26) vs (₹18.05) lakhs (FY25)
- Net Profit/Loss: (₹43.03) lakhs (FY26) vs (₹18.05) lakhs (FY25)
- Basic & Diluted EPS: (₹1.01) (FY26) vs (₹0.42) (FY25)
Share Capital Structure
- Authorized Capital: 50,00,000 equity shares of ₹10 each (₹500 lakhs)
- Issued, Subscribed & Paid-up: 42,73,500 equity shares of ₹10 each (₹427.35 lakhs)
- Capital Reduction: Board and shareholders approved scheme to reduce share capital from ₹427.35 lakhs to ₹42.73 lakhs by writing off ₹384.62 lakhs against accumulated losses (subject to NCLT approval)
AGM Details
- Date: 31st August 2026 at 12:00 PM
- Mode: Video Conferencing/Other Audio Visual Means
- Record Date: 24th August 2026
- Business:
- Ordinary Business: Adoption of financial statements, re-appointment of Mr. Hitesh Bajoria as director
- Special Business: Shifting of registered office from UP to Maharashtra, alteration of MOA, approval of related party transactions
Related Party Transactions Approval
Shareholders approval sought for material related party transactions during period from 34th AGM to 35th AGM (2027) with following limits:
- Cresanto India Private Limited: ₹20 crores
- Cresanto Industries LLP: ₹7.5 crores
- Koriander Consultants LLP: ₹7.5 crores
- Individual promoters/directors: ₹5 crores each
Registered Office Shift
Board approved shifting registered office from C-273, Sector 63, Noida, Uttar Pradesh to Maharashtra, Mumbai subject to shareholder approval and Regional Director confirmation
Business Transition
The company has transitioned from pharmaceutical business to flexible packaging and trading business after EGM approval on 21st April 2025. Company name changed from Raymed Labs Limited to Cresanto Global Limited effective 30th April 2025.
Corporate Governance
- Board Composition: 6 directors (2 independent, 1 executive, 3 non-executive non-independent including 1 woman director)
- Board Meetings: 6 meetings held during FY26
- Committees: Audit Committee (5 meetings), Nomination & Remuneration Committee (1 meeting), Stakeholder Relationship Committee (4 meetings)
- Key Managerial Personnel: Mr. Prashant Bajaj (MD & CFO), Mrs. Pooja Mandave (Company Secretary w.e.f. 28th April 2026)
Liquidity Position
- Cash & Cash Equivalents: ₹0.62 lakhs (31st March 2026) vs ₹0.01 lakhs (31st March 2025)
- Borrowings: ₹280.64 lakhs (unsecured loans from related parties and others)
- Current Ratio: 0.04 (FY26) vs 0.13 (FY25)
- Debt-Equity Ratio: (0.93) (FY26) vs (0.92) (FY25)
Significant Events
- Change in business object from pharmaceuticals to flexible packaging and trading
- Change of company name from Raymed Labs Limited to Cresanto Global Limited
- Proposed reduction of share capital to write off accumulated losses
- Proposed shifting of registered office from Uttar Pradesh to Maharashtra
Compliance Status
- No fraud reported during the year
- No material orders passed by regulators/courts
- No outstanding deposits under Companies Act
- No CSR obligation applicable
- Sexual harassment policy implemented with zero complaints
Future Outlook
The company aims to establish itself as a trusted packaging and trading company globally. The management discussion highlights growth opportunities in the flexible packaging sector projected to reach USD 485.99 billion by FY2034 with 5.8% CAGR.